Research conducted by the MIT Media Lab and Scale AI found that lighter skin tones vastly outnumber darker skin tones in the two of the most widely used dermatology atlases. This led to disparities in an AI model’s ability to diagnose skin conditions involving darker skin tones.
Digital health startup Cognito shared results of a Phase 2 trial of its device, intended to treat Alzheimer’s disease using gamma frequency light and sound. Based on the results, it plans to launch a pivotal study of the treatment.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A discussion on the different models healthcare stakeholders are developing to cover the cost of costly therapies will be just one of the compelling conversations at the virtual conference from December 9-11. Register today!
The study, by researchers at Harvard, MIT, The Broad and other institutions, used genomic analysis of cases linked to the Biogen meeting, linking much of the community transmission in the Boston area to a European genetic variant of SARS-CoV-2 that first appeared at the meeting.
The journal, Rapid Reviews: COVID-19, will use artificial intelligence to scour preprint servers for promising research and allow it to be peer reviewed. Preprint studies have proliferated amid the Covid-19 pandemic, raising concerns about misinformation.
In an article published in the journal mAbs Monday, executives from Adimab alleged that MIT's Ram Sasisekharan copied prior monoclonal antibody research. Visterra, a company Sasisekharan founded that had been developing one of the antibodies, was acquired by Otsuka for $430M last year.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
By passively collecting seizure data, Empatica's device could help patients share medical information with clinicians and make that data easier to manage.
Startup evolution is an iterative process - a marathon. A hackathon can serve as a sprinting start. Here's how you win.
Desktop bioengineering could be a new hobby for those interested in growing and maintaining their own cultures.
After selling its lead product to Allergan last year for $587.5 million, TARIS Biomedical has pivoted into developing a bladder cancer drug device combination with a $32 million investment.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
MIT engineers are tinkering with exercise equipment and centrifuges to come up with the best way to lower the amount of muscle deterioration for long term residents of the International Space Station .
Isn't Theranos supposed to be a smart company? The MIT Technology Review highlights each year what it considers the world's "smartest companies." Understandably, several have been left out.
The Hacking Medicine Institute is rejiggering hackathon concepts so they're applicable to the business of healthcare. But in some ways, it's the anti-hackathon. "At MIT, we love technology," said Ayesha Khalid, co-founder of the Institute. "But I don't think the solution here is more technology."
That flurry of innovation found at a hackathon’s tough to replicate in a business environment. Well, MIT’s going to try and change that. At the close of MIT’s healthcare Grand Hack, the organizers announced they’ll be launching “HackMed Institute,” or the Hacking Medicine Institute, with aims to help educate startups and larger private companies in […]
With precision medicine in its infancy, it’s still difficult to determine which chemotherapy drugs are appropriate for a patient. MIT researchers have developed a device the size of a grain of rice that can be implanted into a patient, and carry small doses of up to 30 different drugs that can be delivered in tandem. When implanted in […]